[go: up one dir, main page]

AU2001232348A1 - Sustained release preparations of physiologically active compound hardly solublein water and production process and use of the same - Google Patents

Sustained release preparations of physiologically active compound hardly solublein water and production process and use of the same

Info

Publication number
AU2001232348A1
AU2001232348A1 AU2001232348A AU3234801A AU2001232348A1 AU 2001232348 A1 AU2001232348 A1 AU 2001232348A1 AU 2001232348 A AU2001232348 A AU 2001232348A AU 3234801 A AU3234801 A AU 3234801A AU 2001232348 A1 AU2001232348 A1 AU 2001232348A1
Authority
AU
Australia
Prior art keywords
production process
active compound
same
sustained release
physiologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001232348A
Inventor
Yasutaka Igari
Shigeru Kamei
Takahito Kitayoshi
Mami Ojima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of AU2001232348A1 publication Critical patent/AU2001232348A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001232348A 2000-02-21 2001-02-20 Sustained release preparations of physiologically active compound hardly solublein water and production process and use of the same Abandoned AU2001232348A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000048980 2000-02-21
JP2000-048980 2000-02-21
PCT/JP2001/001191 WO2001060410A1 (en) 2000-02-21 2001-02-20 Sustained release preparations of physiologically active compound hardly soluble in water and production process and use of the same

Publications (1)

Publication Number Publication Date
AU2001232348A1 true AU2001232348A1 (en) 2001-08-27

Family

ID=18570981

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001232348A Abandoned AU2001232348A1 (en) 2000-02-21 2001-02-20 Sustained release preparations of physiologically active compound hardly solublein water and production process and use of the same

Country Status (5)

Country Link
US (1) US20030068374A1 (en)
EP (1) EP1258254A4 (en)
AU (1) AU2001232348A1 (en)
CA (1) CA2400845A1 (en)
WO (1) WO2001060410A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002034263A1 (en) * 2000-10-25 2002-05-02 Takeda Chemical Industries, Ltd. Preventives/remedies for portal hypertension
US20040121008A1 (en) * 2001-03-16 2004-06-24 Keiko Shiraishi Process for producing sustained release preparation
US7812044B2 (en) 2001-11-13 2010-10-12 Takeda Pharmaceutical Company Limited Anticancer agents
MY131170A (en) * 2002-03-28 2007-07-31 Nissan Chemical Ind Ltd Therapeutic agent for glomerular disease
KR101092279B1 (en) 2002-12-27 2011-12-13 다케다 야쿠힌 고교 가부시키가이샤 Weight gain inhibitors
US20050220881A1 (en) * 2003-10-10 2005-10-06 Bvm Holding Co. Pharmaceutical composition
CA2568640C (en) 2004-06-04 2011-08-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
FR2882260A1 (en) * 2005-02-21 2006-08-25 Flamel Technologies Sa MULTIMICROPARTICULAR ORAL PHARMACEUTICAL FORM WITH MODIFIED RELEASE OF ANTAGONISTS OF ANGIOTENSIN II RECEPTORS
JP2009504800A (en) * 2005-08-22 2009-02-05 アレンビク リミテッド Preparation method of valsartan
PE20081364A1 (en) * 2006-09-04 2008-12-04 Novartis Ag PHARMACEUTICAL COMPOSITION INCLUDING VALSARTAN
EP1897537A1 (en) * 2006-09-04 2008-03-12 Novartis AG Composition comprising an angiotensin II receptor antagonist
BRPI0809522A2 (en) 2007-03-28 2014-10-14 Takeda Pharmaceutical SOLID PHARMACEUTICAL COMPOSITION, METHODS TO STABILIZE A COMPOUND, AND TO IMPROVE DISSOLUTION OF A COMPOUND, AND USE OF A PH CONTROL AGENT.
KR20100047860A (en) * 2007-07-06 2010-05-10 누온 테라피우틱스, 아이엔씨. Treatment of neuropathic pain
AR072883A1 (en) 2008-07-31 2010-09-29 Takeda Pharmaceutical PHARMACEUTICAL COMPOSITION SOLID WITH THE COMPOUND (5-METHYL-2-OXO-1,3-DIOXOL-4-IL) METHYL2-ETOXI-1 - {[2 '- (5-OXO-4,5-DIHIDRO-1,2 , 4-OXADIAZOL-3-IL) BIFENIL-4-IL] METHYL} -1H-BENCIMIDAZOL-7-CARBOXYLATE AND A DIURÉTICO FOR THE PROPHYLAXIS OR TREATMENT OF DISEASES OF THE CIRCULATORY DEVICE.
KR102348320B1 (en) 2014-12-05 2022-01-10 아라곤 파마슈티컬스, 인코포레이티드 Anticancer compositions
KR102387089B1 (en) 2014-12-05 2022-04-14 아라곤 파마슈티컬스, 인코포레이티드 Anticancer compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2151079T3 (en) * 1994-09-09 2000-12-16 Takeda Chemical Industries Ltd PREPARATION OF SUSTAINED RELEASE CONTAINING A METALLIC SALT OF A PEPTIDE.
ATE268591T1 (en) * 1995-06-27 2004-06-15 Takeda Chemical Industries Ltd METHOD FOR PRODUCING DELAYED RELEASE PREPARATIONS
DE69914460T2 (en) * 1998-03-04 2004-10-28 Takeda Chemical Industries, Ltd. PREPARATION WITH DELAYED DELIVERY OF ACTIVE SUBSTANCES FOR AII ANTAGONISTS, THEIR PRODUCTION AND USE

Also Published As

Publication number Publication date
EP1258254A1 (en) 2002-11-20
US20030068374A1 (en) 2003-04-10
WO2001060410A1 (en) 2001-08-23
EP1258254A4 (en) 2004-02-04
CA2400845A1 (en) 2001-08-23

Similar Documents

Publication Publication Date Title
AU2000260550A1 (en) Treatment of skin damage using polyenylphosphatidylcholine
AU2002235140A1 (en) Fluidic self-assembly of active antenna
AU2001232348A1 (en) Sustained release preparations of physiologically active compound hardly solublein water and production process and use of the same
AU2001229712A1 (en) Reduction of hair growth
HUP0300527A3 (en) Pyrrolopyrimidinone derivatives, process of preparation and use
AU2001282267A1 (en) Benzimidazole derivatives, preparation and therapeutic use thereof
AU2002335046A1 (en) The use of proton sequestering agents in drug formulations
AU2001269046A1 (en) Use of therapeutic benzamide derivatives
AU2268301A (en) Novel urea compounds, compositions and methods of use and preparation
AU2001270778A1 (en) Production, stabilisation and use of reduced forms of pharmaceutical compounds
AU2001265253A1 (en) Treatment of hiv using hyperthermia
AU2208401A (en) Inhibitors of complement activation, their preparation and use
AU3622600A (en) Metalloproteinases and methods of use therefor
AU5428700A (en) Acrylic acid derivatives, use of the same and intermediates for the preparation thereof
AU3657100A (en) Use of water-soluble beta-(1,3) glucans as agents for producing therapeutic skintreatment agents
AU2001234089A1 (en) Cancer remedy comprising anthranilic acid derivative as active ingredient
AU2001284763A1 (en) Preparation of risperidone
AU2982000A (en) Preparation of 9-hydrocarbyl-9-phosphabicyclononanes
HUP0302310A3 (en) Novel formulations of alpha-2,4-disulfophenyl-n-tert-butylnitrone and process for their preparation
AU2001241771A1 (en) Use of avocado-soybean unsaponifiable preparations
AU2001265280A1 (en) Preparation of 2-hydroxy-5-oxoproline and analogs thereof
AU2001264863A1 (en) Preparation of fagopyritols and uses therefor
AU3775500A (en) Setting of gemstones
AU2662900A (en) One-pot process for the preparation of 5-sulfonyl-substituted benzotriazoles
AU2001245950A1 (en) Preparation of deoxynucleosides